Dimed S.A. Distribuidora de Medicamentos (BVMF:PNVL3)
Brazil · Delayed Price · Currency is BRL | Market Cap | 1.70B +26.7% |
| Revenue (ttm) | 5.70B +14.6% |
| Net Income | 132.37M +35.9% |
| EPS | 0.88 +34.9% |
| Shares Out | 149.02M |
| PE Ratio | 12.96 |
| Forward PE | 9.42 |
| Dividend | 0.34 (2.96%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 26,200 |
| Open | 11.41 |
| Previous Close | 11.40 |
| Day's Range | 11.39 - 11.65 |
| 52-Week Range | 8.06 - 16.57 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 18.60 (+61.04%) |
| Earnings Date | Aug 13, 2026 |
About BVMF:PNVL3
Dimed S.A. Distribuidora de Medicamentos sells medicines, perfumeries, personal hygiene and beauty products, cosmetics and dermocosmetics in Brazil. It sells its products through physical stores in retail industry. Dimed S.A. Distribuidora de Medicamentos was founded in 1920 and is headquartered in Eldorado do Sul, Brazil. [Read more]
Financial Performance
In 2025, BVMF:PNVL3's revenue was 5.51 billion, an increase of 11.53% compared to the previous year's 4.94 billion. Earnings were 124.61 million, an increase of 18.10%.
Financial StatementsNews
Dimed S.A. Distribuidora de Medicamentos Earnings release: Q1 2026
Dimed S.A. Distribuidora de Medicamentos released its Q1 2026 earnings on June 4, 2026, summarizing the period's financial results.
Dimed S.A. Distribuidora de Medicamentos Slides: Q1 2026
Dimed S.A. Distribuidora de Medicamentos has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 4, 2026.
Dimed S.A. Distribuidora de Medicamentos Slides: Q4 2025
Dimed S.A. Distribuidora de Medicamentos has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 20, 2026.
Dimed S.A. Distribuidora de Medicamentos Earnings release: Q4 2025
Dimed S.A. Distribuidora de Medicamentos released its Q4 2025 earnings on March 20, 2026, summarizing the period's financial results.
Dimed S.A. Distribuidora de Medicamentos Slides: Investor presentation
Dimed S.A. Distribuidora de Medicamentos has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
Dimed S.A. Distribuidora de Medicamentos Earnings Call Transcript: Q3 2025
Q3 2025 saw strong sales growth of 14.3%, robust digital expansion, and a 32.6% rise in private label sales. EBITDA and cash flow improved, while net income was impacted by higher interest rates. The outlook remains positive, with continued focus on digital, private label, and generics.
Dimed S.A. Distribuidora de Medicamentos Earnings release: Q3 2025
Dimed S.A. Distribuidora de Medicamentos released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.
Dimed S.A. Distribuidora de Medicamentos Slides: Q3 2025
Dimed S.A. Distribuidora de Medicamentos has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 7, 2025.
Dimed S.A. Distribuidora de Medicamentos Earnings Call Transcript: Q2 2025
Q2 2025 saw nearly 20% sales growth, strong EBITDA and net income gains, and continued market share expansion, driven by digital, private label, and store expansion strategies. Positive trends are expected to continue, with further margin improvements and growth in key categories.
Dimed S.A. Distribuidora de Medicamentos Earnings release: Q2 2025
Dimed S.A. Distribuidora de Medicamentos released its Q2 2025 earnings on August 15, 2025, summarizing the period's financial results.
Dimed S.A. Distribuidora de Medicamentos Slides: Q2 2025
Dimed S.A. Distribuidora de Medicamentos has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 15, 2025.